Ep. 75 - "Professionals": Dr. Michael Canney, Chief Scientific Officer at Carthera - Cutting edge ultrasound technology for Gliobalstoma treatment
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Ep. 75 - "Professionals": Dr. Michael Canney, Chief Scientific Officer at Carthera - Cutting edge ultrasound technology for Gliobalstoma treatment
-
Narrado por:
-
De:
Acerca de esta escucha
This week on the Let’s Talk F*ng Cancer podcast, we’re diving headfirst into the future of brain cancer treatment with none other than Dr. Michael Canney, Chief Scientific Officer at Carthera — the minds behind the groundbreaking SonoCloud-9®. 🧠⚡
Carthera is revolutionizing how we fight glioblastoma, one of the most aggressive brain cancers out there. With their implantable ultrasound device that opens the blood-brain barrier, they’re giving chemo a chance to actually work — and giving patients a fighting shot. 🙌💊
This isn’t just innovation. It’s a f*ng game-changer.
👂 Tune in to hear how Dr. Canney and the Carthera team are pushing science forward and giving new hope to those battling GBM.
🎧 Available now wherever you get your podcasts!
#LetsTalkFuckingCancer #Glioblastoma #BrainCancer #Carthera #SonoCloud9 #DrMichaelCanney #CancerPodcast #GBM #BreakthroughScience #MedicalInnovation #FuckCancer
Sonobird Clinical Trial
Carthera Advanced Brain Therapy
NeuroNews: Carthera 2023
NeuroNews: Carthera 2024
Biospace: Milestone in SONOBIRD pivotal trial April 2025
Medical Design and Development: Trial begins April 2025